Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.65 EUR | -7.59% | -4.74% | +70.99% |
May. 15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.99% | 1.72B | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.41% | 21.58B | |
-11.30% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target